J Goldman & Company LP Maintains Position in Ptc Therapeutics (PTCT); Nexus Investment Management Upped Its Cenovus Energy (CVE) Stake

May 18, 2018 - By Marguerite Chambers

Cenovus Energy Inc. (NYSE:CVE) Logo

J Goldman & Company Lp increased its stake in Ptc Therapeutics Inc (PTCT) by 13799.66% based on its latest 2017Q4 regulatory filing with the SEC. J Goldman & Company Lp bought 648,584 shares as the company’s stock rose 91.83% while stock markets declined. The hedge fund held 653,284 shares of the health care company at the end of 2017Q4, valued at $10.90 million, up from 4,700 at the end of the previous reported quarter. J Goldman & Company Lp who had been investing in Ptc Therapeutics Inc for a number of months, seems to be bullish on the $1.47B market cap company. The stock increased 0.10% or $0.03 during the last trading session, reaching $31.57. About 396,361 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 274.65% since May 18, 2017 and is uptrending. It has outperformed by 263.10% the S&P500.

Nexus Investment Management Inc increased its stake in Cenovus Energy Inc (CVE) by 131.72% based on its latest 2017Q4 regulatory filing with the SEC. Nexus Investment Management Inc bought 687,840 shares as the company’s stock declined 6.72% with the market. The institutional investor held 1.21M shares of the oil & gas production company at the end of 2017Q4, valued at $11.10M, up from 522,210 at the end of the previous reported quarter. Nexus Investment Management Inc who had been investing in Cenovus Energy Inc for a number of months, seems to be bullish on the $13.57B market cap company. The stock decreased 0.89% or $0.1 during the last trading session, reaching $11.1. About 1.68M shares traded. Cenovus Energy Inc. (NYSE:CVE) has declined 35.61% since May 18, 2017 and is downtrending. It has underperformed by 47.16% the S&P500.

J Goldman & Company Lp, which manages about $1.17 billion and $1.91B US Long portfolio, decreased its stake in Cleveland Cliffs Inc by 966,767 shares to 48,233 shares, valued at $348,000 in 2017Q4, according to the filing. It also reduced its holding in Domtar Corp (NYSE:UFS) by 463,582 shares in the quarter, leaving it with 6,418 shares, and cut its stake in Domtar Corp (Call) (NYSE:UFS).

Since January 3, 2018, it had 0 insider buys, and 4 sales for $61,523 activity. 77 PTC Therapeutics, Inc. (NASDAQ:PTCT) shares with value of $1,361 were sold by Almstead Neil Gregory. Shares for $7,280 were sold by Utter Christine Marie.

Another recent and important PTC Therapeutics, Inc. (NASDAQ:PTCT) news was published by Nasdaq.com which published an article titled: “Analysis: Positioning to Benefit within Entergy, Schneider National, CH Robinson Worldwide, PTC Therapeutics, Guess …” on May 09, 2018.

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 2 Sell and 6 Hold. Therefore 33% are positive. PTC Therapeutics had 40 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was initiated by Jefferies with “Hold” on Friday, October 23. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Sector Perform” rating by RBC Capital Markets on Friday, November 11. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Underweight” rating given on Wednesday, April 4 by Barclays Capital. The firm earned “Hold” rating on Thursday, September 14 by RBC Capital Markets. The rating was upgraded by J.P. Morgan to “Hold” on Thursday, November 16. Citigroup initiated the shares of PTCT in report on Tuesday, August 25 with “Buy” rating. RBC Capital Markets reinitiated PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday, January 29 with “Hold” rating. The stock has “Outperform” rating by Oppenheimer on Friday, October 16. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Outperform” rating given on Monday, November 14 by Credit Suisse. The firm earned “Sell” rating on Monday, October 9 by J.P. Morgan.

Investors sentiment decreased to 0.98 in Q4 2017. Its down 0.73, from 1.71 in 2017Q3. It worsened, as 23 investors sold PTCT shares while 35 reduced holdings. 23 funds opened positions while 34 raised stakes. 35.45 million shares or 7.80% more from 32.89 million shares in 2017Q3 were reported. Guggenheim Capital Ltd invested in 86,908 shares or 0% of the stock. Great Point Limited Co owns 1.09M shares. Northern Tru Corp holds 0% or 667,657 shares in its portfolio. Frontier Management Communications Limited Liability Co reported 0.01% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Alliancebernstein LP owns 49,350 shares. State Common Retirement Fund holds 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 41,800 shares. Royal Retail Bank Of Canada has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). Bnp Paribas Arbitrage reported 8,458 shares. Macquarie Group Incorporated Ltd stated it has 600 shares or 0% of all its holdings. Rhumbline Advisers has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). National Bank & Trust Of Montreal Can reported 810 shares. Moore Ltd Partnership stated it has 0.02% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Sectoral Asset reported 0.78% stake. Spark Investment Mgmt Llc reported 1.04M shares. Deutsche Bank & Trust Ag has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT).

PTC Therapeutics, Inc. (NASDAQ:PTCT) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>